Dyadic International (DYAI) vs Neuphoria Therapeutics (NEUP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dyadic International (DYAI) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 60.7% versus a loss of 81.8%. Neuphoria Therapeutics is the larger company by market cap ($18.1 million vs $17.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | NEUP |
|---|---|---|
| Share price | $0.4444 | $3.35 |
| Market cap | $17.80M | $18.13M |
| 1-day change | -2.65% | -2.05% |
| YTD return | -52.72% | -13.66% |
| 1-year return | -60.67% | -81.76% |
| 5-year return | -90.84% | — |
| EPS (TTM) | $-0.23 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $19.21 |
| 52-week low | $0.34 | $3.19 |
| Distance from 52-week high | -72.23% | -82.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +1137.62% | — |
| Average volume | 201.91K | 161.66K |
| Shares outstanding | 40.06M | 5.41M |
| Employees | 5 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed NEUP by 21.1 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
DYAI vs NEUP FAQ
Which is bigger, Dyadic International or Neuphoria Therapeutics?
Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $18.13M compared with $17.80M for Dyadic International (DYAI).
Which stock has performed better over the past year, DYAI or NEUP?
DYAI returned -60.67% over the past 12 months, compared with -81.76% for NEUP (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and Neuphoria Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Dyadic International and Biotechnology: Pharmaceutical Preparations for Neuphoria Therapeutics.